KRAS and anemia: In an open-label phase 1b/2 study, the anti-CD47 antibody magrolimab combined with cetuximab showed modest efficacy in heavily pretreated CRC, with ORR 6.3% in KRAS wild-type tumors versus 0% in KRAS-mutant tumors (DCR 50.0% vs. 38.1%), and manageable toxicities; grade ≥ 3 anemia occurred in 11.5% of patients and no treatment-related deaths were reported [118].